|
|
 |
|
Viewing report
|
|
|
|
The Gastrointestinal Market Outlook to 2012
Business Insights, Oct 2007, Pages: 189
Gastrointestinal tract disorders (GIT) are a prominent component in the overall disease burden of the world’s most developed economies, and a lack of effective long-term treatments and limited etiological understanding is continuing to exacerbate the impact of such conditions. As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as
Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs.
As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs. ‘The Gastrointestinal Market Outlook to 2012’ is a new report published by Business Insights that provides a detailed epidemiological analysis of key indications within major GIT markets, and examines the factors impacting their prevalence. The dynamics of the market are examined through an analysis of leading brands within each indication and a profile of the pharma companies and market trends influencing the sales of GIT treatments. Forecasts for major product sales over the 2006-12 period are also provided.
Some key findings from this report...
-Products indicated for the treatment of GERD/PUD diseases dominate the global GIT market, valued at $27.8bn in 2006. However, sales over the next five years will decline as a result of increased generic competition caused by impending patent expiries.
-IBS is expected to be the fastest growing therapeutic area within the GIT market, with a forecast CAGR of 14.0% over the 2006-12 period. This growth will be driven by an increased usage of newer IBS products, however past product development failures and limited etiological understanding are potential barriers to expansion.
-Anti-TNF agents are radically changing the treatment of Crohn's disease, particularly in patients with refractory and fistulizing conditions. Although Remicade (infliximab) is currently the only approved anti-TNF agent, Abbott’s Humira (adalimumab) recently won approval from the FDA and EMEA for the treatment of severe Crohn's disease, while UCB Pharma’s Cimzia (certolizumab pegol) has demonstrated promising results and a strong safety profile.
-AstraZeneca’s domination of the GIT market is forecast to continue over the 2006-12 period. The success of Nexium and an impressive launch schedule containing four new products is expected to drive this success.
Top five reasons to order your copy today
-Assess the patient potential, treatment trends and sales patterns of major GIT indications within the key markets of Japan, France, Germany, Italy, Spain, the UK and the US.
-Benchmark the franchises and six year market share forecasts of key players such as AstraZeneca, Wyeth, Abbot, Novartis, J&J, Takeda, Astella, Eisa, Altana and P&G.
-Forecast sales over the 2006-12 period for currently marketed and key pipeline products in major indications and treatment classes.
-Evaluate changes in the promotional spend of major GIT brands and identify the drivers and constraints of portfolio growth for leading companies.
-Understand the licensing trends for major GIT brands and measure the growing influence of generics upon the global market.
Key issues examined in this report...
-Patent expiries in the GERD/PUD market. The impending patent expiries of Prevacid (2009), Nexium (2009), Protonix (2010) and Aciphex (2013), will to lead to a massive influx of generic competition, forcing companies to revise their R&D and portfolio strategies.
-ANDAs threaten Nexium’s market leadership. The EPO’s recent rejection of a substance patent and a significant number of pending ANDA’sare indicators of the continued threat to Nexium’s status within the GERD/PUD market. Despite this, the drug has successfully overcome competition from several branded OTC’s and the generic omeprazole.
-Future of IBS and IBD. There is a clear market need for effective IBS and IBD treatments. However, past treatment failures and limited etiological understanding have created difficulties in acheiving the clinical efficacy and safety profiles required for success.
-Success of labelling extensions. J&J’s Remicade and Abbot’s Humira are set for continued success through 2012 due to labelling extensions.
Your questions answered...
-Which indications have the highest growth potential over the
next five years?
-How have recent GIT product launches performed?
-Who were the GIT market’s best and worst performing companies in 2006?
-Which compounds in development have the greatest forecast potential?
-How will the competitive landscapes of therapy areas such as GERD, PUD, IBS, Crohn’s disease and Ulcerative Colitis change over the 2006-12 period?
-Which companies are best positioned for future success?
-How significant will the threat of generics be over the 2006-12 period?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Telvent Git SA
The Gastrointestinal Market Outlook to 2010
Thought Leader Insight & Analysis: Gastrointestinal Disorders -- UC, Crohn's, OIC, GERD
Global Overview of the Polyurethane Dispersions (PUD) Market
Allergy Drug Pipeline and R&D 2009
Allergy Drug Pipeline and R&D 2009
The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
The Autoimmune Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The Dermatology Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The Anti-Infectives Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
IBS AG
|
|
|
|
